Sarepta (SRPT) Sees Modest Selling Amid $225M Stock Offering

September 21, 2016 4:06 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Sarepta Therapeutics (NASDAQ: SRPT) is down just 0.7% on plans to offer $225 million in common stock. The stock has more than doubled this week after announcing FDA approval.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Equity Offerings, Momentum Movers, Trader Talk

Add Your Comment